Protalix BioTherapeutics, Inc. (PLX)

AMEX · Pharmaceuticals & Biotech · Biological Products, (No Diagnostic Substances)

Price
$2.75
Day
+2.23%
Market cap
$221.57M
P/E
11.7

Close 2026-09-21.

The company

We are a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension. ProCellEx®, our unique, proprietary plant cell-based protein expression system represents a new method for developing recombinant proteins in an industrial-scale manner. To date, we have successfully developed two commercial products, both of which are enzyme replacement therapies (ERTs): Elelyso ® (taliglucerase alfa) for the treatment of adult patients and children four years of age and older with Gaucher disease and Elfabrio ® (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease. Elelyso, our first commercial product, is our proprietary recombinant form of glucocerebrosidase (GCD), an enzyme naturally found in human cells that is mutated or deficient in patients with Gaucher disease . Elelyso was approved by the FDA in 2012 for injection as an ERT for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in more than 40 markets including the United States, Brazil, Israel and others. It is not approved in the European Union (EU).

By product & service

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

Insider trades

Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.

Recent filings